|
|

| General
Information |

Common Name: |

Evening Primrose Oil (abbreviated EPO) |
|
Latin
Name:
|
Oenothera
biennis L. |
|
Family:
|
Onagracaeae |
| Other
Names: |
 |
King's
Cure-All
|
|
| Indications
& Historical Uses |
|
For
centuries, native American tribes have used evening primrose both
as a food and a remedy for a variety of ailments. In
the seventeenth century, the plant was imported from North America
and naturalized in Europe. For the last three centuries, folk
healers have used evening primrose to treat myriad ailments.
Infusions made from the entire evening primrose plant were used
as an astringent for the skin and as a treatment for anxiety,
stomach and intestinal disorders, asthma and whooping cough.
Poultices made from the evening primrose plant were used externally
to encourage wound healing.
The
healing properties of the evening primrose plant are still recognized
today; however, research has revealed that it is the small,
reddish seed of the evening primrose that endows the plant with
its biological activity. Modern-day herbalists and health-care
practitioners recommend the oil extracted from the small,
reddish seeds of the evening primrose plant for use in therapeutic
herbal preparations. Evening primrose oil (EPO) is currently
recognized as being beneficial for use in:
 |
Treatment
of rheumatoid arthritis – studies show that EPO may help
reduce or eliminate requirement for non-steroidal anti-inflammatory
medications.
|
 |
Treatment
of inflammatory skin diseases (e.g. eczema,psoriasis) –
research indicates that ingestion of EPO and/or topical
use of EPO (i.e. application of contents of capsule to the
skin) can relieve itching and eliminate the need for use
of anti-inflammatory steroidal medications; safe for use
in children and adults.
|
 |
Treatment
and prevention of heart disease and stroke; helps to reduce
blood pressure – EPO has been shown to reduce blood cholesterol
levels by an average of 31.5% and it additionally helps
to reduce platelet aggregation (i.e. prevents blood clot
formation)
|
 |
Treatment
and prevention of PMS symptoms such as bloating, breast
tenderness, depression, irritability, headaches, etc.
|
 |
Improves
skin condition – helps to produce and maintain healthy condition
of skin
|
 |
Helps
to reverse neurologic damage of advanced diabetes and aids
in the normalization of certain lipid metabolic factors
involved in the disease process of diabetes
|
 |
Treatment
of ulcerative colitis
|
 |
Treatment
of symptoms of multiple sclerosis – EPO has been shown to
help treat the symptoms of MS; many trials are currently
underway to help quantify its usefulness for patients suffering
from MS
|
 |
Treatment
of breast pain, for example, in conditions such as fibrocystic
breast disease
|
 |
Helps
to reduce symptoms of alcohol withdrawal and to increase
speed of liver healing following liver damage due to chronic
use of alcohol or medications
|
 |
Helps
to kill tumor cells in test tube and live animal studies
– studies are currently underway to identify which human
cancers are most susceptible to the effects of EPO
|
 |
Helps
to reduce and retard hair loss (seen in alopecia and male pattern
baldness)
|
 |
Treatment
of infertility, especially in men
|
 |
Helps
to strengthen immune system function |
 |
Raynaud’s
phenomenon
|
 |
Sjogren’s
syndrome
|
 |
Menopausal
flushing spells |
|
| Contraindications
& Precautions |
|
Contraindications:
None known. See
Caution.
Precautions:
None. See
Caution.
Adverse
Side Effects:
None known. Numerous toxicity studies have shown that EPO is a
very safe herbal medication with a sound safety profile. See
Caution.
Drug
Interactions:
No significant interactions preclude the use of EPO. However,
black currant and borage oils are known to have similar effects
to EPO, so it is important to adjust the dosage of EPO if taking
these herbal medications simultaneously. Also, EPO is known to
reduce blood clotting activity, so it is best to consult a physician
before taking EPO in conjunction with other anticoagulants(blood
thinning medications). Rare possibility of seizures in patient’s
with schizophrenia treated with phenothiazine drugs and evening
primrose oil. See
Caution.
|
| Dosage
Information |
|
How
Supplied:
|
 |
Capsule
(liquid filled) (Bionutrix formulation is a liquid-filled
capsule.)
|
 |
Liquid
|
 |
Oil
|
 |
Tablet
|
|
|
Dosage:
|
The
recommended dosage is 500mg taken up to three times per day. The
disorder one wishes to treat or prevent may lead to some variation
in the recommended dose or dosing schedule. Instructions for common
ailments or conditions are as follows:
For
PMS:
A dosage of 500 mg EPO taken up to three times per day is recommended
; should be taken 2 to 3 days before the expected onset of symptoms
(i.e. usually 10 days before the onset of menstruation).
For
cardiovascular or inflammatory disorders:
A daily dosage of 500mg to 1000mg per day of EPO (containing between
1g to 2g of GLA) is recommended.
For
eczema:
For atopic eczema, a smaller daily dosage of 250mg to500mg per
day of EPO (approximately equivalent to 250mg to 500mg of GLA)
is recommended.
|
| Pharmacology
|
|
The
seeds of the evening primrose plant are comprised of about 14%
of a particular oil (evening primrose oil, EPO) which has a fixed
composition. Evening primrose oil contains a high concentration
of essential fatty acids (EFAs), the most important of which are
the essential polyunsaturated fatty acids known as gamma-linoleic
acid (GLA) and cis-linoleic acid. EPO contains about 7
to 10% GLA and 50 to 70% cis-linoleic acid. When ingested,
gamma-linoleic acid is converted to a precursor form of the hormones
known as prostaglandins. These hormones serve a variety of biological
functions, ranging from mediating inflammatory processes to moderating
pain sensations and influencing blood clotting processes. The
myriad functions of prostaglandins and the involvement of EPO
in prostaglandin metabolism confer a wide variety of therapeutic
properties upon the evening primrose seed.
See
Indications and Historical Uses (above) for a comprehensive list
of uses for EPO.
Essential
fatty acids, and GLA in particular, are required to maintain a
healthy heart, as well as healthy skin, blood vessels, joints
and various other healthy organs. The human body cannot manufacture
essential fatty acids from any other compounds; therefore, EFAs
must be obtained from dietary sources or supplements which contain
ready-made EFAs. EPO capsules are one such source of EFAs. Gamma-linoleic
acid is one of the most biologically important EFAs, and most
people usually manufacture it as needed from ingested cis-linoleic
acid. However, GLA itself is not available in significant quantity
in any particular food, and it is for this reason that evening
primrose oil is recommended as a supplement for people who would
benefit from larger, therapeutic quantities of GLA and for people
who have a metabolic defect which prevents them from converting
cis-linoleic acid into GLA(e.g. in patients with atopic
eczema).
Factors
such as stress, aging, high cholesterol, alcohol, diabetes, PMS,
viral infections, and other conditions may interfere with the
normal conversion of linolenic acid into GLA. In these conditions
the patients would benefit from larger therapeutic doses of evening
primrose oil-a rich source of GLA.
Many
studies have verified the effectiveness of EPO as a medicinal
herb. EPO has the added advantage of being a very safe preparation
- toxicity studies have shown that it has a solid safety profile
when used at recommended therapeutic dosages. However, it is important
to purchase EPO from a reliable manufacturer of herbal preparations,
since a 1991 study has shown that most North American preparations
contain no evening primrose oil at all, being comprised instead
of pure safflower oil. It is therefore imperative to verify that
the manufacturer has dose-standardized the EPO preparation and
can guarantee that all capsules contain at least the minimum therapeutic
dose of gamma-linoleic acid and/or evening primrose oil.
|
|
Active
Ingredients:
|
The
evening primrose seed contains 14% evening primrose oil, of which
7 to 10% is gamma-linoleic acid (GLA) and 50-70% is cis-linoleic
acid. Both GLA and cis-linoleic acid are essential
fatty acids (EFAs). Evening primrose oil also contains other
EFAs, which further contribute
to its biological activity.
The
human body cannot manufacture EFAs, and these must therefore be
obtained from the diet or from supplements such as EPO capsules.
EFAs are required to maintain a healthy heart, as well as healthy
skin, blood vessels, joints and various organs.
|
|
Enhancing
Agents:
|
None known. |
| Origin |
|
The
evening primrose is a wildflower native to eastern North America.
Despite its common name, it is not a true primrose. It is, however,
a member of the primrose family, Onagraceae. This hardy plant
grows in dry, sandy or stony soil and is commonly found in waste
sites, on sandy dunes and near railway embankments. The plant
grows to a height of about three to four feet, with lance-shaped,
hairy leaves and large, attractive, four-petal lemon yellow flowers
which bloom along the length of a branched reddish stem ending
in a spike at the apical tip. The plant derives its name from
the odd behaviour of the flowers, which open only at night. The
flower blooms from mid-to late summer, at which point the blooms
fall off. The blooms are then replaced by tubular, pointed seed
pods which house small, reddish seeds containing an oil rich in
a number of essential fatty acids (EFA’s), most notably gamma-linoleic
acid (GLA) and and cis-linoleic acid. It is the properties
of the EFA’s which give the evening primrose its biological activity;
therefore, the seeds of the plant are used to produce the medicinal
herbal extract
|
| Processing |
|
The
small, reddish seeds of the evening primrose plant are harvested
from the tubular, pointed seed pods of the mature plant in the
mid- to late summer, when they contain a peak concentration of
EFA’s. The large, pale yellow flowers fall off of the plant during
the summer, and they are then followed by the tubular, pointed
seed pods.
Bionutrix
harvests the seeds from the tubular pods of special, organically-grown
wild evening primrose plants in late summer, when they are of
peak potency. The seeds are carefully-extracted and crushed and
then subjected to extraction in a special, organically-derived
safflower oil-based medium designed to extract and dissolve all
of the EFA’s which give the plant its therapeutic properties.
This EFA-rich liquid is then spectrographically-analyzed to determine
the concentration, which is then standardized for GLA. The precisely-standardized
oil-based formulation is then encapsulated in a non-reactive gelatin
capsule in 250mg doses of EPO. Bionutrix produces the most reliably
dose-standardized, purest and most potent organic extract of evening
primrose oil and encapsulates it in an easy-to-swallow, soft gelatin
capsule. All Bionutrix capsules are guaranteed to contain a precisely-standardized
therapeutic dose of EPO in a hypo-allergenic medium of organic
safflower oil.
|
| Scientific
References |
 |
American
Pharmaceutical Association. Handbook of Nonprescription Drugs.
11th ed. Washington,D.C.: American Pharmaceutical
Association. |
 |
Belch,
J.J., et al. Annals of the Rheumatic Diseases, 47(2)(1988):96-104.
|
 |
Berth-Jones,
J. and Graham-Brown, R.A. The Lancet, 341(8860)(1993):1557-60.
|
 |
Biagi,
P.L., et al. Drugs Under Experimental and Clinical Research,
14(4)(1988):285-90.
|
 |
Field,
E.F. The Lancet, 1(1978):780.
|
 |
Gately,
C.F., and Mansel, R.E. British Medical Bulletin, 47(1991):284.
|
 |
Ghayor,
T., and Horrobin, D.F. IRCS Medical Science, 9(1981):582.
|
 |
Glen,
I., et al. Alcoholism, Clinical and Experimental Research,
11(1987):37-41.
|
 |
Greenfield,
S.M., et al. Alimentary Pharmacology and Therapeutics, 7(2)(1993):159-66.
|
 |
Horrobin,
D.F. Journal of Reproductive Medicine, 28(7)(1983):465-68.
|
 |
Horrobin,
D.F. Medical Hypotheses, 5(1979):365.
|
 |
Horrobin,
D.F., and Manku, M.S. Paper presented at the annual meeting
of the Intl. Conference on Oils, Fats and Waxes. Auckland,
1983.
|
 |
Jamal,
G.A. The Lancet, 1(1986):1098.
|
 |
Joe,
L.A. and Hart, L.L. Annals of Pharmacotherapy, 27(12)(1993):1475-77.
|
 |
Kerscher,
J.J., and Korting, H.C. Clinical Investigator, 70(2)(1992):167-71.
|
 |
Lawrence
Review of Natural Products. St.Louis: Facts and Comparisons,
November 1993.
|
 |
Leung,
A.Y., and S.Foster. Encyclopedia of Common Natural Ingredients
Used in Food, Drugs, andCosmetics. 2nd ed. New
York: John Wiley & Sons, 1996. |
 |
Leventhal,
L.J., et al. Annals of InternalMedicine, 119(9)(1993):867-73.
|
 |
Mindell,
E. Earl Mindell’s Herb Bible. New York: Simon and Schuster/Fireside,
1992.
|
 |
Poulaka,
J., et al. Journal of Reproductive Medicine. 30(1985):149
|
 |
Ramesh,
G., et al. Nutrition, 8(5)(1992):343-47.
|
 |
Stewart,
A. Journal of Reproductive Medicine, 32(6)(1987):435-41.
|
 |
Takahashi,
R., et al. Prostaglandins, Leukotrienes, and Essential Fatty
Acids, 49(2)(1993):569-71.
|
 |
Traitler,
H., et al. Lipids, 19(12)(1984):923-28
|
 |
Trease,
G.E., and W.C. Evans. Trease and Evans’ Pharmacognosy. 13th
ed. Philadelphia: BailliereTindall, 1989. |
 |
Tyler,
V.E. Herbs of Choice: The Therapeutic Use of Phytomedicinals.
Binghampton, N.Y.:Haworth Press/Pharmaceutical Products Press,
1994. |
 |
Weiss,
R.F. Herbal Medicine, trans. A.R.Meuss, from the 6th
German edition. Beaconsfield, England:Beaconsfield Publishers,
Ltd., 1988. |
 |
Wright,
S. Acta Dermato-Venereologica. Supplementum, 114(1985):143-45.
|
|
 EVENING PRIMROSE OIL |
|